Myovant Spurns Sumitovant Offer, Remains Open To Higher-Value Deal

Sumitomo Pharma Subsidiary Already Owns 52%

 
• By Mandy Jackson
Balance of stones on a blue sky background
Myovant's board established a special committee to weigh Sumitovant's offer and future proposals • Source: Shutterstock

More from Deals

More from Business